Report: Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology TOC

1 Executive Summary

2 Table of Contents

2.1 List of Boxes
2.2 List of Figures
2.3 List of Tables

3 Methodology

4 Introduction to Apoptosis in Oncology

5 Apoptosis Competitive Landscape in Oncology

5.1 Countries & Players: Who are In the Lead?
5.1.1 Top 10 Players Dominate The Developmental Pipeline
5.2 Deals & Alliances in Apoptosis Drug Development
- 5.2.1 Review of Deals and Alliances Initiated in 2006
- 5.2.2 Review of Deals and Alliances Initiated in 2005
- 5.2.3 Review of Deals and Alliances Initiated in 2004
- 5.2.4 Review of Deals and Alliances Initiated in 2003
- 5.2.5 Review of Deals and Alliances Initiated in 2002
- 5.2.6 Review of Deals and Alliances Initiated in 2001

6 Approved Apoptopic Cancer Drugs: Performance

7 Target Analysis in Apoptosis

7.1 Targets of Late Stage Apoptopic Drugs in Development
- 7.1.1 B-cell CLL/lymphoma 2
- 7.1.2 Caspase 3
- 7.1.3 CD4 molecule
- 7.1.4 Cytosolic ovarian carcinoma antigen 1
- 7.1.5 Eukaryotic translation elongation factor 2
- 7.1.6 Farnesyltransferase, CAAX box, alpha
- 7.1.7 Fc fragment of IgE
- 7.1.8 Histone deacetylase 1
- 7.1.9 Histone deacetylase 2
- 7.1.10 Interleukin 13 receptor, alpha 1
- 7.1.11 Phosphodiesterase 2A, cGMP-stimulated
- 7.1.12 Phosphodiesterase 5A, cGMP-specific
- 7.1.13 Protein kinase C, beta 1
- 7.1.14 Steroid 5-alpha-reductase, alpha polypeptide 1
- 7.1.15 Topoisomerase (DNA) I
- 7.1.16 Topoisomerase (DNA) II alpha
- 7.1.17 Tubulin, beta polypeptide
- 7.1.18 p53 protein
7.2 Apoptopic Drugs and Their Targets According to Top 5 Cancer Indications
- 7.2.1 Targets in Breast Cancer
- 7.2.2 Targets in Leukemia
- 7.2.3 Targets in Lung Cancer
- 7.2.4 Targets in Lymphoma
- 7.2.5 Targets in Prostate Cancer

8 Apoptopic Drugs in Development: By Major Indications

8.1 General Drug Developmental Overview
- 8.1.1 Apoptopic Drugs in Phase III Clinical Development
- 8.1.2 Failed Apoptopic Drugs in Oncology
8.2 Progress Analysis - Breast Cancer
- 8.2.1 Phase I Clinical Development
- 8.2.2 Phase II Clinical Development
- 8.2.3 Phase III Clinical Development
8.3 Progress Analysis - Leukemia
- 8.3.1 Phase I Clinical Development
- 8.3.2 Phase II Clinical Development
- 8.3.3 Phase III Clinical Development
8.4 Progress Analysis - Lung Cancer
- 8.4.1 Phase I Clinical Development
- 8.4.2 Phase II Clinical Development
- 8.4.3 Phase III Clinical Development
8.5 Progress Analysis - Lymphoma
- 8.5.1 Phase I Clinical Development
- 8.5.2 Phase II Clinical Development
- 8.5.3 Phase III Clinical Development
8.6 Progress Analysis - Prostate Cancer
- 8.6.1 Phase I Clinical Development
- 8.6.2 Phase II Clinical Development
- 8.6.3 Phase III Clinical Development

9 Immunotherapy in Oncology

9.1 Vaccine Strategies: Challenges & Opportunities
9.2 Key Antibody Developmental Strategies

10 Competitive Landscape in Cancer Vaccines

10.1 Countries & Players: Who are In the Lead?
- 10.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
- 10.1.2 Approved Cancer Vaccine Drugs: Performance
10.2 Deals & Alliances in Cancer Vaccines
- 10.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
- 10.2.2 Deals in Prostate Cancer
- 10.2.3 Deals in Breast Cancer
- 10.2.4 Deals in Leukemia & Lymphoma
- 10.2.5 Drug Delivery Deals in Cancer Vaccines
- 10.2.6 Adjuvant Deals

11 Antibody Deals on the Rise

11.1 Antibody Deals in Phase III
- 11.1.1 Deal Situation: MDX 010
- 11.1.2 Deal Situation: WX G250
- 11.1.3 Deal Situation: Zanolimumab
11.2 Antibody Deals in Phase II
- 11.2.1 Deal Situation: Mapatumumab
- 11.2.2 Deal Situation: GCR 3888
- 11.2.3 Deal Situation: MDX 070
- 11.2.4 Deal Situation: CDP 860
- 11.2.5 Deal Situation: Tru-Scint OV
- 11.2.6 Deal Situation: SC 1
- 11.2.7 Deal Situation: PRO 70769
- 11.2.8 Deal Situation: XR 303
- 11.2.9 Deal Situation: HumaRAD-HN

12 Tumor Antigens

12.1 Tumor Antigens: General Comments
12.2 Antigen Discovery
- 12.2.1 Classical Immunology Approach
- 12.2.2 The Reverse Immunology Approach
- 12.2.3 Company Platforms
12.3 Specific Antigen Processing Technologies Increasing Antigen Presentation

13 Immunomodulators & Adjuvants in Cancer Vaccines

13.1 Overview
13.2 Cytokines
- 13.2.1 Vaccines in Combination with Interleukin-2
- 13.2.2 Tumor Necrosis Factor
- 13.2.3 Interferons
13.3 Adjuvants
13.4 Other Immunomodulating Strategies
- 13.4.1 An Immune Response Modifying Protein
- 13.4.2 Immunostimulatory DNA
- 13.4.3 Ex Vivo Stimulated Immune Cells
- 13.4.4 Fusion Protein Gain Potent Immune Response
- 13.4.5 Macrophage and Natural Killer Cells Activation
- 13.4.6 Selective Suppression of the Immune System to An Antigen
- 13.4.7 TAP Technology

14 Cancer Vaccine Delivery

14.1 Viral Delivery
- 14.1.1 Introduction
- 14.1.2 Viral Constructs Put into Use
14.2 Bacterias
14.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
- 14.3.1 Introduction
- 14.3.2 Cell Therapy Strategies
14.4 Synthetic Delivery Systems & Strategies
- 14.4.1 Introduction
- 14.4.2 Biotransport™
- 14.4.3 Biotype®vector
- 14.4.4 DNAVax Gene Delivery System
- 14.4.5 FusitAb™
- 14.4.6 GeneDrug™
- 14.4.7 Molecular Conjugates
- 14.4.8 Naked DNA Delivery
- 14.4.9 PVLP Technology
- 14.4.10 Sphingosomal Drug Delivery Technology
- 14.4.11 STEALTH
- 14.4.12 Failed Liposomal Systems

15 New Approaches in Antibody Delivery and Design - The Next Generation

15.1 How to Make Them Smaller and Different?
15.2 Biomaterials in Sustained Delivery Applications
- 15.2.1 Implants
15.3 Gene delivery - the Future?
- 15.3.1 Delivery Vehicles for DNA
- 15.3.2 Gene Delivery in Commercialization

16 Cancer Vaccines in Development: By Major Indications

16.1 General Oncology Overview
16.2 Progress Analysis - Melanoma
16.3 Progress Analysis - Breast Cancer
16.4 Progress Analysis - Prostate Cancer
16.5 Progress Analysis - Lung Cancer
16.6 Progress Analysis - Colorectal Cancer
16.7 Progress Analysis - Cervical Cancer

17 Antibodies in Clinical Development

17.1.1 Prostate Cancer Therapeutics
17.1.2 Breast Cancer Therapeutics
17.1.3 Colorectal Cancer Therapeutics
17.1.4 Melanoma Therapeutics
17.1.5 Hematological Cancers Therapeutics
17.2 Antibodies in Phase III Clinical Development
- 17.2.1 Progress Analysis: IGN 101
- 17.2.2 Progress Analysis: MDX 010
- 17.2.3 Progress Analysis: ONYVAX 105
- 17.2.4 Progress Analysis: Ovarex
- 17.2.5 Progress Analysis: Panitumumab
- 17.2.6 Progress Analysis: RENCAREX
- 17.2.7 Progress Analysis: Nimotuzumab
- 17.2.8 Progress Analysis: TransMID
- 17.2.9 Progress Analysis: Lintuzumab
- 17.2.10 Progress Analysis: Zanolimumab
17.3 Antibodies in Phase II Clinical Development
- 17.3.1 Progress Analysis: ABT-510
- 17.3.2 Progress Analysis: BB 10901
- 17.3.3 Progress Analysis: CP 675206
- 17.3.4 Progress Analysis: CNTO-328
- 17.3.5 Progress Analysis: Ecromeximab
- 17.3.6 Progress Analysis: EMD 273063
- 17.3.7 Progress Analysis: WX-G250RIT
- 17.3.8 Progress Analysis: HGS-ETR1
- 17.3.9 Progress Analysis: HuMax-CD20
- 17.3.10 Progress Analysis: HuMax-EGFr
- 17.3.11 Progress Analysis: Galiximab
- 17.3.12 Progress Analysis: PROXINIUM
- 17.3.13 Progress Analysis: RAV12
- 17.3.14 Progress Analysis: SGN-15
- 17.3.15 Progress Analysis: SGN-30
- 17.3.16 Progression Analysis: VEGF-Trap
- 17.3.17 Progress Analysis: MEDI 522
- 17.3.18 Progress Analysis: Volociximab

18 Disclaimer

19 Company Index

20 Drug Index

List of Boxes

Box 1: Business & Market - PXD-101
Box 2: Business & Market - MG-98
Box 3: Business & Market - VX-680
Box 4: Business & Market - Ceflatonin
Box 5: Business & Market - Oblimersen sodium
Box 6: Business & Market - motexafin gadolinium
Box 7: Business & Market - 1D09C3
Box 8: Business & Market - PCK-3145
Box 9: Business & Market - ME-2
Box 10: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction
Box 11: M-VAX - Business & Market Bakground
Box 12: Gardasil: Business & Market Background
Box 13: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology
Box 14: TNF in Cancer Treatments
Box 15: Marrion' s Drug Delivery Technology
Box 16: Quick Facts - IGN 101
Box 17: Quick Facts - MDX 010
Box 18: Quick Facts - ONYVAX 105
Box 19: Quick Facts - Ovarex
Box 20: Quick Facts - Panitumumab
Box 21: Quick Facts - RENCARNEX
Box 22: Quick Facts - Nimotuzumab
Box 23: Quick Facts - RENCARNEX
Box 24: Quick Facts - Lintuzumab
Box 25: Quick Facts - Zanolimumab
Box 26: Quick Facts - ABT-510
Box 27: Quick Facts - BB 10901
Box 28: Quick Facts - CP-675206
Box 29: Quick Facts - CNTO-328
Box 30: Quick Facts - Ecromeximab
Box 31: Quick Facts - EMD-273063
Box 32: Quick Facts - WX-G250RIT
Box 33: Quick Facts - HGS-ETR1
Box 34: Quick Facts - HuMax-CD20
Box 35: Quick Facts - HuMax-EGFr
Box 36: Quick Facts - Galiximab
Box 37: Quick Facts - PROXINIUM
Box 38: Quick Facts - RAV12
Box 39: Quick Facts -SGN-15
Box 40: Quick Facts -SGN-30
Box 41: Quick Facts - VEGF-Trap
Box 42: Quick Facts - MEDI 522
Box 43: Quick Facts - Volociximab

List of Figures

Figure 1: Top 5 Countries in Apoptopic Cancer Research
Figure 2: Top 10 Companies' Clinical Trial Progress in Apoptopic Drug Development
Figure 3: Trial Distribution of the Entire Apoptopic Pipeline in Oncology
Figure 4: Distribution of ApoptopicTrials in Breast Cancer
Figure 5: Distribution of Apoptopic Drug Trials in Leukemia
Figure 6: Distribution of Apoptopic Drug Trials in Lung Cancer
Figure 7: Distribution of Apoptopic Drug Trials in Lymphoma
Figure 8: Distribution of Apoptopic Drug Trials in Prostate Cancer
Figure 9: Top 10 Countries in Cancer Vaccine Research
Figure 10: Top 10 Companies' Clinical Trial Progress in Cancer Vaccine
Figure 11: 2003-2005 Deals & Alliances in Cancer Vaccine
Figure 12: Distribution of Cancer Vaccine Trials in Melanoma
Figure 13: Distribution of Cancer Vaccine Trials in Breast Cancer
Figure 14: Distribution of Cancer Vaccine Trials in Prostate Cancer
Figure 15: Distribution of Cancer Vaccine Trials in Lung Cancer
Figure 16: Distribution of Cancer Vaccine Trials in Colorectal Cancer
Figure 17: Distribution of Cancer Vaccine Trials in Cervical Cancer

List of Tables

Table 1: Top 10' s Apoptopic Pipeline Drugs
Table 2: Deals & Alliances in Apoptosis Drug Development in Oncology
Table 3: Companies with Apoptopic Cancer Drugs on the Market
Table 4: List of 120 Known Targets in Apoptosis Drug Development
Table 5: Known Targets of Late Stage Apoptopic Drugs Development
Table 6: Drugs with Bcl-2 as a Target
Table 7: Drugs with Casp-3 as a Target
Table 8: Drugs with CD4 molecule as a Target
Table 9: Drugs with Cova-1 as a Target
Table 10: Drugs with Eef-2 as a Target
Table 11: Drugs with Fnta as a Target
Table 12: Drugs with Fcer-2 as a Target
Table 13: Drugs with Hdac-1 as a Target
Table 14: Drugs with Hdac-2 as a Target
Table 15: Drugs with IL13-RA1 as a Target
Table 16: Drugs with Pde-2A as a Target
Table 17: Drugs with Pde-5A as a Target
Table 18: Drugs with Prkcb-1 as a Target
Table 19: Drugs with Srd-5A1 as a Target
Table 20: Drugs with Top-1 as a Target
Table 21: Drugs with Top-2A as a Target
Table 22: Drugs with Top-2A as a Target
Table 23: Drugs with p53 protein as a Target
Table 24: Breast Cancer Targets in Apoptopic Drug Development
Table 25: Leukemia Targets in Apoptopic Drug Development
Table 26: Lung Cancer Targets in Apoptopic Drug Development
Table 27: Lymhoma Targets in Apoptopic Drug Development
Table 28: Prostate Cancer Targets in Apoptopic Drug Development
Table 29: Top 10 Cancer Indications in Apoptopic Cancer Drugs
Table 30: Overview of Apoptopic Drugs in Phase III Clinical Development
Table 31: Recently Ceased or Discountinued Phase I to Phase III Apoptopic Drugs
Table 32: List of Phase I to Phase III Apoptopic Drugs in Development for Breast Cancer
Table 33: List of Phase I to Phase III Apoptopic Drugs in Development for Leukemia
Table 34: List of Phase I to Phase III Apoptopic Drugs in Development for Lung Cancer
Table 35: List of Phase I to Phase III Apoptopic Drugs in Development for Lymphoma
Table 36: List of Phase I to Phase III Apoptopic Drugs in Development for Prostate Cancer
Table 37: Summary of Strategies Enhancing Antibody Function
Table 38: Companies with Cancer Vaccine Drugs on Market
Table 39: Antigen Classification
Table 40: Platforms Used to Improve Antigen Presentation
Table 41: Cancer Vaccines in Clinical Trials in Combination with Interleukin-2
Table 42: Adjuvants in Cancer Vaccines
Table 43: Synthetic Delivery Systems Deployed in Cancer in General and Cancer Vaccines in Particular
Table 44: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
Table 45: Drug Delivery Companies with Cancer Focus
Table 46: FDA Approved Polymer-based Drug Delivery Systems for Cancer
Table 47 Top 10 Cancer Indications in Non-Antibody Based Cancer Vaccines
Table 48: Discountinued Phase I to Phase III Cancer Vaccine Drugs
Table 49: List of Phase I to Phase III Cancer Vaccines in Development for Melanoma
Table 50: List of Phase I to Phase III Cancer Vaccines in Development for Breast Cancer
Table 51: List of Phase I to Phase III Cancer Vaccines in Development for Prostate Cancer
Table 52: List of Phase I to Phase III Cancer Vaccines in Development for Lung Cancer
Table 53: List of Phase I to Phase III Cancer Vaccines in Development for Colorectal Cancer
Table 54: List of Phase I to Phase III Cancer Vaccines in Development for Cervical Cancer
Table 55: Antibody Therapeutics in Prostate Cancer
Table 56: Antibody Therapeutics in Breast Cancer
Table 57: Antibody Therapeutics in Colorectal Cancer
Table 58: Antibody Therapeutics in Melanoma
Table 59: Antibody Therapeutics in Hematological Cancer
Table 60: MDX-010' s Collaborative History and Landscape